Jean‐Pierre Armand

Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

Sandrine Faivre, Catherine Delbaldo, Karina Vera et al. · Journal of Clinical Oncology · 2005 · 1.2K citations · Full text

Pharmacy, Oncology, Pharmacology +17

A phase II study

Philippe Rougier, Antoine Adenis, Michel Ducreux et al. · European Journal of Cancer · 2000 · 752 citations

Public Health, Biostatistics, Experimental Design +4

Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer

Éric Raymond, Jérôme Alexandre, Sandrine Faivre et al. · Journal of Clinical Oncology · 2004 · 500 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.

D Abigerges, G G Chabot, Jean‐Pierre Armand et al. · Journal of Clinical Oncology · 1995 · 299 citations

Medicine, Oncology, Pharmacology +17

Inhibition of Cellular Mediated Immunity in Marihuana Smokers

Gabriel G. Nahas, Nicole Suciu‐Foca, Jean‐Pierre Armand et al. · Science · 1974 · 236 citations

Life Sciences, Immunology, Cellular Immunology +13